Clinical Trials Browser

Leukemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, T-Cell, Leukemia, Myeloid, Acute, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT00253318 2025-04-27

RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer

Phase 1 Terminated

15 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT05432518 2025-04-25

Pilot Trial for Treatment of Recurrent Glioblastoma

Phase EARLY_PHASE1 Recruiting

10 enrolled

CNS

Glioblastoma, Recurrence

NCT03324373 2025-04-24

Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)

Phase 1 Completed

11 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT04339062 2025-04-23

CONTRAC

Phase 1/2 Completed

12 enrolled 13 charts

Dermatologic

Cutaneous Squamous Cell Carcinoma

NCT03114527 2025-04-04

Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

Phase 2 Active not recruiting

48 enrolled

Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

Clinical Trials

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

LEVEL

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

EVER-RECODE

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

MOMENTUM-1

LEVER

POLARIS

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

EVOLVE-BDT

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

BIOMEDE 2

RAF/MEK

GERTRUDE

Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer

ESMART

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

CERTICOEUR

Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma

Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer

Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations

MOST plus

Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer

A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection

Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019)

Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy

SEQTOR

RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma

Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis

Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer

Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma

RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer

Pilot Trial for Treatment of Recurrent Glioblastoma

Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)

CONTRAC

Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)